Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 9

1.

Clinical and economic outcomes associated with amlodipine/renin-angiotensin system blocker combinations.

Ferrario CM, Panjabi S, Buzinec P, Swindle JP.

Ther Adv Cardiovasc Dis. 2013 Feb;7(1):27-39. doi: 10.1177/1753944712470979. Epub 2013 Jan 17.

PMID:
23328188
2.

Antihypertensive efficacy of olmesartan medoxomil or valsartan in combination with amlodipine: a review of factorial-design studies.

Ram CV.

Curr Med Res Opin. 2009 Jan;25(1):177-85. doi: 10.1185/03007990802597456 . Review.

PMID:
19210150
3.

Olmesartan/Amlodipine: combination therapy for the treatment of hypertension [corrected].

Pimenta E.

Adv Ther. 2009 Jan;26(1):1-11. doi: 10.1007/s12325-008-0132-9. Epub 2009 Jan 7. Review. Erratum in: Adv Ther. 2009 Jan;26(1):126.

PMID:
19129998
4.

Amlodipine and valsartan as components of a rational and effective fixed-dose combination.

Waeber B, Ruilope LM.

Vasc Health Risk Manag. 2009;5(1):165-74. Epub 2009 Apr 8. Review.

6.

Comparative clinical- and cost-effectiveness of candesartan and losartan in the management of hypertension and heart failure: a systematic review, meta- and cost-utility analysis.

Grosso AM, Bodalia PN, Macallister RJ, Hingorani AD, Moon JC, Scott MA.

Int J Clin Pract. 2011 Mar;65(3):253-63. doi: 10.1111/j.1742-1241.2011.02633.x. Epub 2011 Feb 1. Review.

PMID:
21284790
7.

Angiotensin II type 1 receptor blockade: high hopes sent back to reality?

Grothusen A, Divchev D, Luchtefeld M, Schieffer B.

Minerva Cardioangiol. 2009 Dec;57(6):773-85. Review.

PMID:
19942847
8.

A literature review to evaluate the clinical and economic value of olmesartan for the treatment of hypertensive patients.

Kourlaba G, Gialama F, Tsioufis K, Maniadakis N.

Int J Cardiol. 2016 Oct 15;221:60-74. doi: 10.1016/j.ijcard.2016.06.115. Epub 2016 Jun 24. Review.

PMID:
27404671
9.

Supplemental Content

Support Center